Complete this form to download G-Rex bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production.
For production of human lymphocytes for cell therapy, a contamination control strategy (CCS) is required as part of current Good Manufacturing Practices (cGMP). Evidence of successful CCS approaches will go a long way to ensuring safety, purity, efficacy and quality of a cell therapy. Microbial contamination and non-viable particulate contamination are the top two reasons for FDA injectable pharmaceuticals from 2009 to 2019.
By selecting this option, you are acknowledging that you have read and understand our Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.